Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Sulfones. Found 4 abstracts

Deng XB, Xiao L, Wu Y, Jin F, Mossman B, Testa JR, Xiao GH. Inhibition of mesothelioma cancer stem-like cells with adenovirus-mediated NK4 gene therapy. International journal of cancer. 2015 Jul 15;137(2):481-90.   PMCID: PMC4428975
Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br J Cancer. 2014 Nov 11;111(10):1932-44.   PMCID: Pmc4229637
Ding PR, Tiwari AK, Ohnuma S, Lee JW, An X, Dai CL, Lu QS, Singh S, Yang DH, Talele TT, Ambudkar SV, Chen ZS. The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter. PLoS One. 2011 Jan;6(4):e19329.   PMCID: PMC3084276
Makhov P, Golovine K, Uzzo RG, Rothman J, Crispen PL, Shaw T, Scoll BJ, Kolenko VM. Zinc chelation induces rapid depletion of the X-linked inhibitor of apoptosis and sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Cell death and differentiation. 2008 Nov;15(11):1745-51.   PMCID: PMC2585550
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Sulfones

metabolism Sulfones drug effects pharmacology pathology Male Tumor Cell Line chemistry antagonists & inhibitors Notch Receptors Molecular Models Hepatocyte Growth Factor Aged Chelating Agents IGF Type 1 Receptor Caspases Adenoviridae drug therapy Neoplasm Staging Phase II Clinical Trials as Topic therapeutic use P-Glycoprotein Tertiary Protein Structure Tissue Distribution Antitumor Drug Screening Assays Piperazines Zinc Lung Neoplasms Propionates Indoles beta Catenin TNF-Related Apoptosis-Inducing Ligand Genetic Vectors Benzene Derivatives deficiency Copper Prostatic Neoplasms Nude Mice Neoplastic Stem Cells Protein Conformation Follow-Up Studies Biological Models Ethylamines HGF Randomized Controlled Trials as Topic Carbolines therapy enzymology Enzyme Activation cancer stem-like cells malignant mesothelioma Cellular Spheroids Type 5 Cyclic Nucleotide Phosphodiesterases physiology genetics Intracellular Space Imidazoles analogs & derivatives Adult Triazines Proteasome Endopeptidase Complex Western Blotting Genetic Therapy Phosphorylation Sirolimus Middle Aged methods Neoplastic Gene Expression Regulation Neoplasms TOR Serine-Threonine Kinases Phase III Clinical Trials as Topic 3-Ring Heterocyclic Compounds Monoclonal Antibodies Cell Survival Met Female Nk4 Proto-Oncogene Proteins c-met Cohort Studies Prognosis Pyrimidines Protease Inhibitors Neoplasm Drug Resistance Xenograft Model Antitumor Assays Proto-Oncogene Proteins c-akt Apoptosis Antineoplastic Combined Chemotherapy Protocols KB Cells Mesothelioma Fluorescence Microscopy pharmacokinetics X-Linked Inhibitor of Apoptosis Protein Small Interfering RNA Phosphodiesterase 5 Inhibitors 80 and over Aged Adenosine Triphosphatases Biological Tumor Markers
Last updated on Thursday, August 13, 2020